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ABSTRACT
Objective: This study aims to determine the pathophysiology of vulvar vestibulitis and to evaluate
currently used treatment options.
Methods: Two hundred twenty women with vulvar vestibulitis were seen between October 1987
and March 1995. Every patient had vulvar pain when they attempted intercourse, 75% had exces-
sive vaginal discharge, 36.4% had constant or recurring vulvar burning, and 10.9% had symptoms
suggestive of cystitis. All were cultured for the presence of Candida albicans. One hundred sixty-one
(73.2%) were also tested for vaginal IgE and prostaglandin E2 (PGE2); 72 (32.7%) had a vulvar
biopsy performed as well.
Results: A wide range of variants were noted: 53 (24.1%) had a human papilloma virus (HPV)
infection, 25 (11.4%) had a Candida vulvovaginitis, 43 (19.5%) had a vaginal allergy, 15 (6.8%) had
vaginal PGE2 present, 14 (6.4%) had elevated urinary oxalate excretion, and 29 (13.2%) had a
variety of diagnosed variants. In 81 (36.8%) no underlying diagnosis was made. This understates
the numbers and varieties of vulvar vaginal diagnoses, for not all patients received a vaginal fluid
analysis, a vulvar biopsy, or a 24 h urine screen for oxalates. A variety of medical and operative
interventions was used. Symptoms were relieved in 65.9% of patients. The degree of success varied.
Successful outcomes were achieved in 14.3% of patients using a low oxalate diet and calcium citrate
supplementation, 16% with anti-Candida treatment, 48.1% with antihistamines, 77% with vulvar
injection of interferon, 83% with operative removal of inflamed vulvar tissue, and a posterior
colporrhaphy used to cover the cutaneous defect.
Conclusions: The diagnosis of vulvar vestibulitis is easy to make. An etiology for this chronic
condition will not be achieved in every patient. A majority of patients can get relief by a variety of
medical and operative interventions. Infect. Dis. Obstet. Gynecol. 4:269-275, 1996.
(C) 1997 Wiley-Liss, Inc.
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ihysicians should be cognizant of the syndrome
of vulvar vestibulitis. Adult women with this
painful, socially debilitating malady need emo-
tional support and appropriate medical care. Unfor-
tunately, because of the lack of awareness of this
condition, these positive interventions are often
not offered. Specific diagnostic techniques must be
carried out by the physicians to make the diagnosis,
and the majority of patients can be helped by phy-
sician treatment. This requires physician patience
to deal with a chronic medical problem. It is the
purpose of this paper to review our experience with
vulvar vestibulitis in the Department of Obstetrics
and Gynecology at the New York Hospital-Cornell
University Medical Center.
MATERIALS AND METHODS
The 220 women in this report were all seen in
consultation in the time interval from October 1987
until March 1995. Only 4 patients were seen in
1987 and 1988, and then the numbers of consulta-
tions increased during the last 6 years surveyed. All
patients had a vaginal pH determination and a mi-
croscopic examination of the vaginal secretions us-
ing saline and potassium hydroxide solution. In 161
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TABLE I. Symptoms
Pain 220 (100%)
Excessive vaginal discharge 165 (75%)
Vulvar burning 80 (36.4%)
Urinary tract symptoms 24 (10.9%)
(73.2%) of the patients, a fluid sample was col-
lected for Candida culture and determination of
IgE and prostaglandin Ez (PGE z) levels. This test-
ing was not done in some women who had no vagi-
nal symptoms and it was declined by some patients
due to cost considerations usually because of mem-
bership in a Health Maintenance Organization or
some other insurance payment plan that would not
reimburse the patient for this test. All of the
women who did not have vaginal fluid testing had
a culture performed for the presence of yeast and
bacteria. Seventy-two patients (32.7%) with a vul-
var area that turned white after the application of
4% acetic acid were biopsied and those with mi-
croscopic evidence of active human papilloma virus
(HPV) infection had a colposcopic examination
performed.
RESULTS
These patients ranged in age from 19 to 63 years,
with a median age of 32 years. All had a history of
dyspareunia so intense that it eliminated the pos-
sibility of sexual intercourse. All had severe point
tenderness when a cotton-tipped applicator was ap-
plied to small reddened vestibular gland sites at
specific anatomic locations. These women had a
wide variety of other symptoms (Table 1): 165
(75%) complained of a persistent vaginal discharge,
80 (36.4%) had constant or recurring vulvar burn-
ing, and 24 (10.9%) had repeated urinary tract
symptoms suggestive of a cystitis, but had no sig-
nificant bacterial growth on urine culture.
During their diagnostic evaluations, there was a
wide variety of vulvovaginal findings. These find-
ings are noted in Table 2. HPV was the most com-
mon infection found in this population of women:
53 (24.1%) had a history or present evidence on
vulvar biopsy of HPV infection. Thirty-five
(15.9%) had a history of HPV infection treated by a
variety of local agents, including trichloroacetic
acid (TCA), 5-fluorouracil (5-FU), or local laser. In
12 of these patients vulvar pain began after treat-
TABLE 2. Abnormalities discovered
HPV 53 (24.1%)
Allergic vaginitis (elevated IgE) 43 (19.5%)
Candida vaginitis 25 (I 1.4%)
Elevated PGE 15 (6.8%)
Elevated urinary oxalates 14 (6.4%)
Miscellaneous 29 (I 3.2%)
Desquamative vaginitis 12 (5.5%)
Micropapillomatosis 9 (4. I%)
Herpes 4 (I.8%)
Chlamydia trachomatis 2 (0.9%)
Neisseria gonorrhoeae (0.45%)
Bacterial vaginosis (0.45%)
Idiopathic 81 (36.8%)
ment, following laser in 8 cases, 5-FU in 3 cases,
and TCA in case. Of the 18 cases with active
HPV infection, 13 were treated with local inter-
feron injections. A positive culture for Candida al-
bicans was found in 25 women (11.4%). Twenty-
four of these 25 women (96%) complained of an
excessive vaginal discharge. Many patients without
Candida also had a discharge, 145 of 195 (72.3%).
These differences are statistically significant. Chi-
square using the Yates correction is 5.43 (P < 0.05).
Despite this, only 24 of the 165 women (14.5%)
with an abnormal discharge were culture positive
for Candida. Candida was detected on microscopic
examination in only 13 of these 15 culture positive
cases (52%). Candida forms were also seen on mi-
croscopic examination in 2 women who were cul-
ture negative. Vaginal IgE, indicating a local vagi-
nal allergy, was found in 43 of the 161 women
(26.7%) tested. These 43 women represent 19.5%
of the total of the 220 patients who were evaluated.
Vaginal PGEe as the only positive finding was de-
tected in 15 of the 160 screened (9.4%), or 6.8% of
the total patient population. Fifteen women who
had failed treatment with hydroxyzine or antihis-
tamines had a 24 h urine analysis done by Dr. Sol-
omon to evaluate oxalate excretion, e Fourteen
(93.3%) of these tests were positive, or 6.4% of the
total population. Another 29 (13.2%) had a variety
of diagnosed variants: 12 (5.5%) had desquamative
vaginitis, 9 (4.1%) had micropapillomatosis labialis,
4 (1.8%) had recurring genital herpes, 2 (0.9%) had
Chlamydia trachomatis, (0.45%) had Neisseria gon-
orrhoeae, and (0.45%) had bacterial vaginosis. In
81 women (36.8%), no underlying diagnosis was
made. The total in Table 2--260uis related to the
fact that some women had more than one abnor-
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TABLE 3. Treatment outcomes
Antihistamines 102 of 212 (48. I%)
Operations 25 of 30 (83%)
Interferon 10 of 13 (77%)
Anti-Candida 4 of 25 (16%)
Low oxalate diet and 2 of 14 (14.3%)
citrate ingestion
Other 2
almproved: 145 of 220 (65.9%).
mality noted. Table 2 obviously understates the
numbers and varieties of vulvovaginal pathology
for all patients who did not receive a vaginal fluid
analysis, a vulvar biopsy, or a 24 h urine screen for
oxalates. For example, a recent polymerase chain
reaction (PCR) screen for HPV found it present in
54% of 46 operative samples ofwomen with vulvar
vestibulitis, e Prior to our seeing these patients, all
had been evaluated for the presence of N. gonor-
rhoeae and most had been screened for C. trachoma-
tis. At the time of our evaluation, we did not do a
PCR for C. trachomatis or Trichomonas vaginalis and
no serum antibody testing was done for herpes sim-
plex virus-2 (HSV-2).
Any analysis of treatment requires a definition
of physician assessment of patient response to
therapy. Few women were totally cured of the
symptoms noted in Table 1. After treatment
deemed successful by this group of investigators all
patients were not completely free of pain, vaginal
discharge, vulvar burning, or urinary tract symp-
toms. The satisfactory treatment response noted in
Table 3 indicates an improvement in patient symp-
tomatology to the point that they were able to have
intercourse again. We also observed some patients
classified as a cure who had a recurrence of pain,
particularly in the postpartum period. This symp-
tom flare-up responded to medical treatment.
The treatment outcomes are noted in Table 3.
Only 65.9% were cured after a variety of treat-
ments. Some explanations are necessary for the
analysis of these results. All but 8 of the 220
women received either hydroxyzine or an antihis-
tamine when they were first seen. In those patients
who failed to respond to this initial therapy, and
whose vaginal secretions and cultures showed no
evidence of a specific etiology, a biopsy or alterna-
tive therapy was used. A urine screen for oxalate
excretion was reserved for treatment failures who
had persistent vulvar burning, while an operation
was performed in treatment failure patients who
continued to have severe pain when they at-
tempted intercourse. This accounts for the small
numbers in those treatment categories.
The treatment results were less promising than
expected (Table 3). Less than half, 102 of 212
(48.1%), of the women treated with hydroxyzine or
an antihistamine responded to therapy. Almost all
patients had some improvement in symptoms, but
the majority did not have enough pain relief to
resume having intercourse. This poor response was
even true in the 43 women who had allergic vagi-
nitis confirmed by the presence of an elevated IgE
in vaginal secretions; 42 or 43 were treated, with 21
cured (50%). Of the 118 tested women without IgE
present, 110 were treated with antihistamines and
53 were cured (48.2%). These differences are not
statistically significant. Thirty of the 220 women
who failed to respond to medical treatment had an
operation with removal of the vestibular glands and
the inflamed vulvar tissue. A posterior colporrha-
phy was done to mobilize the posterior wall of the
vagina and this was used as a graft to cover the
cutaneous defect caused by the operation. Twenty-
five of 30 women (83%) were improved by this
approach, although 2 of these women required 2
operations to get a satisfactory result. In 13 women
with a symptomatic vulvar HPV infection, 12 sepa-
rate interferon injections, each one million units of
alpha 2B, were given subcutaneously in the vulva
over a 4 week interval. Ten (77%) had a satisfactory
response with relief of pain 6-8 weeks after therapy
and no gross posttreatment changes in the vulvar
epithelium were noted. Other treatment regimens
had a much lower success rate. Twenty-three of
the 25 women (92%) had Candida eliminated from
the vagina on follow-up culture after oral anti-
Candida treatment. However, only 4 (16%) had re-
lief of symptoms. Fourteen of 15 women who sub-
mitted 24 h urine samples for oxalate evaluations
had elevated levels, but only 2 of the 14 (14.3%)
were able to tolerate the low oxalate diet and the
recommended high calcium citrate regimen for the
long periods of time that were required. Despite
this discouraging treatment picture, there are glim-
mers of hope. In this study population of 220
women, 20 (9.1%) became pregnant and success-
fully carried their pregnancies to term. In addition,
no serious underlying diseases were found in this
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population of women during this time interval of
observation.
DISCUSSION
Physician awareness of this syndrome, vulvar ves-
tibulitis, is important. Too many obstetrician-
gynecologists fail to diagnose this syndrome. For
the symptomatic patient, this translates into a se-
ries of visits to many different doctors in which the
recurring physician response is a lack of recognition
of the problem. Since the busy doctors, overbur-
dened with large numbers of patients with easily
recognized conditions, such as pregnancy, do not
see any gross abnormalities, they dismiss the pa-
tient. These women leave with a new layer of iat-
rogenic concern; since their physicians see no pa-
thology, perhaps their symptoms are not real.
The physician should have no difficulty in mak-
ing the diagnosis of vulvar vcstibulitis. A directed
history will yield crucial facts. All of these women
have introital pain when they try to have inter-
course. For most patients, their vulvar discomfort is
only related to attempts to have intercourse, but in
this study population, over a third of the women
had constant vulvar burning (see Table 1). The
majority of the 220 women (75%) have an excessive
vaginal discharge and a minority (10.9%) had
chronic urinary tract symptomatology. The number
of patients with lower urinary tract symptoms
(10.9%) is lower than the 44% reported by McCor-
mack.4 After obtaining a history, the diagnosis can
be confirmed at the time of physical examination.
Pressure with a cotton-tipped applicator stick at
specific pressure points (picture the vulva as the
face of a clock) at 3:30 and 8:30 elicits excruciating
pain. This physical diagnosis finding of pain at a
specific anatomic site whose small vestibular gland
openings are easily identified is the reason we favor
the terminology vestibular adenitis for this syn-
drome. It is a reminder of an important physical
diagnosis abnormality. Other authors4,s have used
the designation focal vulvitis; they object to the
term vestibular adenitis for they do not find in-
flamed vestibular glands in the pathology speci-
mens of these patients. We do not dispute this for
in our review of the pathologic specimens in this
series, this was the exception rather than the rule.
In contrast, a histopathologic study of 41 cases of
vulvar vestibulitis found vestibular glands present
in 66% of the cases.6 The frequency of involve-
ment of the vestibular glands in operative speci-
mens may be related to the number of microscopic
sections obtained. We acknowledge the contro-
versy about naming this syndrome and accept the
current designation vulvar vestibulitis.6 Whatever
terminology is used, the diagnosis can be con-
firmed by the physician within minutes at the time
of the initial examination with the use of a cotton-
tipped applicator stick.
Although there is no common infectious agent
in this syndrome, clinical observations suggest a
uniform response in the progression and mainte-
nance of the pain of vestibular adenitis. Most of
these women have the onset of symptomatology
associated with a specific local inflammatory event.
The triggering factor can vary. This can be inflam-
matory vulvitis due to an HPV infection, vulvovag-
initis due to C. albicans, an allergic vulvovaginitis,
or inflammation resulting from the local treatment
of "fiat warts," particularly by laser. What distin-
guishes these patients from most women with an
inflammatory vulvovaginitis is the persistence of
the inflammation and pain.
Some physicians have likened the persistent
vulvar pain in this syndrome to the sympathetic
dystrophy syndrome.7 They theorize that cutane-
ous vulvar disturbances destabilize the pelvic floor
muscles. This destabilization of the pelvic muscles
perpetuates vulvar tissue inflammation by its ef-
fects on locally autonomic (sympathetic) mediated
activity. This results in vulvar vascular changes and
histamine release. This theory parallels the clinical
observations in these patients and is the justifica-
tion for many of the medications used. Hydroxy-
zine reduces sympathetic nerve activity and relaxes
pelvic muscles. Antihistamines block the effects of
the local release of histamines. Laser in the rapid
super pulse mode has been used to eliminate ex-
cessive vascularization.8 Biofeedback has been em-
ployed to correct pelvic floor disability. 7 All of
these regimens help some but not all patients.
Some studies have suggested a psychologic com-
ponent to this syndrome and suggest that stress
plays a role in dyspareunia and vulvar pain.9,1 One
study demonstrated improved results when psy-
chologic treatment was included in the regimen.
9
These theories are a search for an explanation for
the chronic nature of this problem.
Currently available therapeutic strategies for
these patients can be frustrating for both the pa-
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tient and the physician. These women have a
chronic vulvar inflammatory problem that usually
requires long periods of time, i.e., months, to
achieve a satisfactory response. In addition, suc-
cessful therapy often necessitates more than one
type of therapeutic intervention to achieve a cure.
Besides the focus on the causes of the local vulvar
inflammation, the physician has to be cognizant of
the pelvic floor muscle destabilization and sympa-
thetic nerve hyperactivity which perpetuate the
vulvar inflammation and pain. A variety of ap-
proaches have been utilized to minimize these re-
sponses.
Therapy begins with a search for an etiology for
the continued vulvar inflammation. If this is found,
specific medications can be prescribed. The pa-
tient response rate varies with each determined
source of inflammation. The treatment.results shed
some light on the pathophysiology of this chronic
condition.
Our outcomes in patients with Candida infec-
tions provide insights for therapy strategy. Candida
vulvovaginitis was documented by a positive cul-
ture in 25 women (11.4%) of the total. They had
expected symptomatology. Twenty-four of 25
women (96%) of this subpopulation complained of
an excessive vaginal discharge. Although an exces-
sive vaginal discharge was more common in women
culture positive for Candida (96% vs. 71.8%), phy-
sicians caring for women with vulvar vestibulitis
must be cautious in attributing the excessive vagi-
nal discharge to a Candida infection. There are two
reasons for this caution. Candida is an uncommon
cause of this symptomatology. Only 24 of the 165
women (14.5%) with an abnormal vaginal discharge
were culture positive for Candida vaginitis. In ad-
dition, Candida vaginitis is a difficult diagnosis to
make in this population. Only 13 of the 25 culture
positive women (52%) had yeast forms detected in
the wet mount microscopic examination of vaginal
secretions that were Candida culture positive.
These results are not unexpected for they are simi-
lar to those reported by McCormack et al. 11 in their
evaluation ofwomen with a symptomatic yeast vag-
initis. In women with vulvar vestibulitis, diagnosis
of a yeast infection requires culture confirmation.
Beside diagnostic difficulties, there are treatment
problems. Our treatment results show that Candida
infections were not an important factor in maintain-
ing the vulvar pain suffered by these women. The
anti-Candida oral treatment was effective in elimi-
nating Candida, but it relieved symptoms in only 4
of 25 (16%). The failure of patient symptom re-
sponse to antifungal treatment should not be a sig-
nal for continued long-term antifungal treatment.
In this population, these women remained symp-
tomatic despite a microbiologic cure. Continued
antifungal treatment for a culture negative patient
has no rationale and increases the possibility of an
adverse reaction to antifungal medications, particu-
larly local forms such as creams and suppositories
containing propylene glycol.
Our results with attempts to decrease urinary
oxalate secretion were just as disappointing as the
antifungal treatment. Only 2 of 14 (14.3%) had an
improvement in symptoms. It is difficult for us to
gauge the significance of excessive oxalate excre-
tion in this population. Based upon laboratory
evaluations done by Dr. Solomon’s laboratory, it
was a common problem. Fourteen of the 15 women
surveyed (93.3%) had excessive oxalate excretion.
Although commonly found when tests were done,
the treatment results were poor. Only 2 of the 14
(14.3%) had an improvement in symptoms with a
low oxalate diet and heavy calcium citrate inges-
tion. Although these patients were counseled be-
fore treatment that up to 6 months of therapy
would be necessary for a cure, the lack of improve-
ment and the diminished quality of life with the
diet and abdominal bloating with the citrate caused
12 of the 14 to stop treatment.
In contrast, the immunologic treatment of pa-
tients with an active HPV infection was associated
with a higher incidence of success. Ten of 13 such
women (77%) treated with local interferon injec-
tions were cured. This is a long course of treat-
ment. The acute treatment phase, 12 injections
given 3 times/week, requires 4 weeks for comple-
tion. The posttreatment recovery phase is 8 weeks
before a judgment can be made about success or
failure of treatment. Despite this length of time,
the therapeutic response was gratifying. There was
a high cure rate and the treatment failures had no
vulvar scarring with which to contend.
The physician caring for women with vulvar
vestibulitis should be alert to the possibility of local
allergy. Forty-three women (19.5%)of the total had
evidence of a local vaginal allergy. The treatment
results were disappointing. All but of these pa-
tients were treated with antihistamine for several
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months and only 21 patients (50%) were improved.
A major diagnostic and therapeutic problem in
women with an allergic vaginitis is that the vaginal
IgE is not present in the serum. This eliminates
the possibility of skin testing for specific antigens
so that the patient can avoid future exposure. This
would be a preferable option if it were available.
The high frequency of vaginal allergy in women
with vulvar vestibulitis should be acknowledged by
physicians when vaginal IgE testing is not avail-
able. Many of these women are sensitive to local
creams and suppositories which contain propylene
glycol. These local agents should be avoided.
The results of this study indicate that treatment
strategy must look beyond immediate causes of
vulvar irritation. There are a number of observa-
tions that support this view. When a specific trigger
for the irritation was determined, not all of the pa-
tients were cured. There was a wide range of suc-
cess from 14.3% in those with excessive oxalate
excretion to 77% in those with an active HPV in-
fection treated with interferon (see Table 3). In the
case of Candida, a microbiologic cure did not
equate with clinical success. In the others, the fail-
ure in part could be related to shortcomings of the
therapy. In addition to these treatment failures,
there were 81 women (36%) of the total in whom
no discernible cause of the vulvar irritation was
discovered. These numbers might have been lower
if a vulvar biopsy had been performed in every
patient.2 If therapy is focused solely upon obvious
causation of the vulvar irritation, a large segment of
the patient population has no hope for relief.
Long-term treatment is needed to achieve a
clinical cure. The best explanation for the results
seen is that autonomic nerve dysfunction results in
continuing vulvar irritation and destabilization of
the pelvic muscles. Success of antihistamines or
hydroxyzine was only noted after months of
therapy. It was found in 21 of 42 (50%) of the
patients with a demonstrable vaginal allergy. This
therapeutic intervention was almost as successful
when used in those tested women without a vagi-
nal allergy. Fifty-three of 110 tested women
(48.2%) who were treated responded. The re-
sponse of these patients to antihistamines when no
local allergy was detected reinforces the hypothesis
that neurologic disturbances (i.e., autonomic nerve
dysfunction) may also trigger histamine release.
The low rate of success with hydroxyzine and
antihistamines has spurred an interest in alternate
therapeutic approaches. Biofeedback methods
have been noted to have success in some patients
with this chronic vulvar problem.7 We believe our
high success rate with operative intervention (83%)
is related to postoperative therapy that addresses
the problem of pelvic muscle destabilization. After
the vulvar sutures have reabsorbed, we place these
patients on a program of progressive introital dila-
tation with vaginal dilators. These are used in pro-
gressively larger sizes over a 6 week period, before
intercourse is attempted. These women discover
with this progressive program that the vagina can
accept objects the size of an erect male penis with-
out pain. This process of patient controlled vaginal
dilatation has been a major factor in our high op-
erative success rate, but a recent study by
Goetsch le had excellent results without this post-
operative care. Other factors are important in any
assessment of operative intervention. In this series,
operations were the last therapeutic resort for pa-
tients who were medical treatment failures, whose
problem was pain without constant vulvar burning.
We believe this is important. A rush to operation as
initial treatment will yield failures and the subse-
quent management of these women is difficult.
Operation should not be the first line of care.
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